secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0000950170-25-042129
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics amends license deal with WY Biotech; delays $4M upfront payment, adds June 2025 termination option
--------------------------------------------------------------------------------

- Amended License, Research and Co-Development Agreement dated November 17, 2024, due to CDMO delay.
- Restructured $7.0M upfront license fee; initial $4.0M portion originally due March 17, 2025, delayed.
- Performance milestones for earning full $7.0M nonrefundable upfront payment reduced; deadline June 2025.
- Either party may terminate if WY Biotech cannot definitively engage its CDMO by June 2025.
- No other material changes; HCW retains Opt-In Right for Americas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025042129/0000950170-25-042129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025042129/hcwb-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer